A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers

Journal of Ocular Pharmacology and Therapeutics

Volumn 32, Issue 8, 2016, Pages 548-554

  Laties, Alan ^a   Rich, Cadmus C ^b   Stoltz, Randall ^c   Humbert, Vernon ^d   Brickman, Chaim ^b   McVicar, William ^b   Baumgartner, Rudolf A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INOTEK CORPORATION   (United States)

^c Covance Global Clinical Pharmacology ^*  (United States)

^d Evansville Heart Center   (United States)

Author keywords

adenosine; intraocular pressure; ocular hypertension; primary open angle glaucoma; trabecular meshwork; Trabodenoson

Indexed keywords

DRUG METABOLITE; INO 2446; PLACEBO; TRABODENOSON; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE EXCORIATION; APPLICATION SITE PAIN; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHEILITIS; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; FEMALE; HEADACHE; HEMATOMA; HORDEOLUM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OCULAR PRURITUS; PAPULAR RASH; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL IMPAIRMENT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EYE; INTRAOCULAR HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EYE; HEALTHY VOLUNTEERS; HUMANS; MIDDLE AGED; OCULAR HYPERTENSION;

EID: 84992188123     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2015.0147     Document Type: Article

References (17)

1. Gordon, M. O., Beiser, J. A., Brandt, J. D., et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:714-720; discussion 829-830, 2002.
2. Kass, M. A., Heuer, D. K., Higginbotham, E. J., et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713, 2002.
3. Leske, M. C., Heijl, A., Hussein, M., et al. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch. Ophthalmol. 121:48-56, 2003.
4. Heijl, A., Leske, M. C., Bengtsson, B., Hyman, L., Bengtsson, B., and Hussein, M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120:1268-1279, 2002.
5. Kass, M. A., Gordon, M. O., Gao, F., et al. Delaying treatment of ocular hypertension: The ocular hypertension treatment study. Arch. Ophthalmol. 128:276-287, 2010.
6. Sanderson, J., Dartt, D. A., Trinkaus-Randall, V., et al. Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Muller cells, lens, trabecular meshwork, cornea and lacrimal gland. Exp. Eye. Res. 127:270-279, 2014.
7. Avila, M. Y., Stone, R. A., and Civan, M. M. A(1)-, A(2A)-and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse. Br. J. Pharmacol. 134:241-245, 2001.
8. Tian, B., Gabelt, B. T., Crosson, C. E., and Kaufman, P. L. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp. Eye. Res. 64:979-989, 1997.
9. Crosson, C. E., and Gray, T. Characterization of ocular hypertension induced by adenosine agonists. Invest. Ophthalmol. Vis. Sci. 37:1833-1839, 1996.
10. Crosson, C. E. Adenosine receptor activation modulates intraocular pressure in rabbits. J. Pharmacol. Exp. Ther. 273: 320-326, 1995.
11. Crosson, C. E., and Gray, T. Modulation of intraocular pressure by adenosine agonists. J. Ocul. Pharmacol. 10: 379-383, 1994.
12. Crosson, C. E. Ocular hypotensive activity of the adenosine agonist (R)-phenylisopropyladenosine in rabbits. Curr. Eye. Res. 11:453-458, 1992.
13. Daines, B. S., Kent, A. R., McAleer, M. S., and Crosson, C. E. Intraocular adenosine levels in normal and ocularhypertensive patients. J. Ocul. Pharmacol. Ther. 19:113-119, 2003.
14. Shearer, T. W., and Crosson, C. E. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 43:3016-3020, 2002.
15. Zhong, Y., Yang, Z., Huang, W. C., and Luo, X. Adenosine, adenosine receptors and glaucoma: An updated overview. Biochim. Biophys. Acta. 1830:2882-2890, 2013.
16. Crosson, C. E., Sloan, C. F., and Yates, P. W. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest. Ophthalmol. Vis. Sci. 46: 3795-3799, 2005.
17. Lu, Z., and Xu, S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB. Life. 58:621-631, 2006.